
- © Arturo Ciccullo
- , et al.
- 2022
Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice
- Arturo Ciccullo 1,2
- Gianmaria Baldin 3,4
- Alex Dusina 3,4
- Maria Vittoria Cossu 5,6
- Francesca Lombardi 7
- Alberto Borghetti 8
- Amedeo Capetti 9
- Simona Di Giambenedetto 8
- 1 - Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive
- 2 - Università Cattolica del Sacro Cuore - Roma Italy
- 3 - Fondazione Policlinico Universitario A. Gemelli IRCCS
- 4 - UOC Malattie Infettive - Roma Italy
- 5 - Division of Infectious Diseases Department of Infectious Diseases
- 6 - Luigi Sacco University Hospital - Milano Italy
- 7 - Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive - Università Cattolica del Sacro Cuore - Roma Italy
- 8 - Fondazione Policlinico Universitario A. Gemelli IRCCS - UOC Malattie Infettive - Roma Italy
- 9 - Division of Infectious Diseases - Department of Infectious Diseases - Luigi Sacco University Hospital - Milano Italy
May 06, 2022
Abstract
The GEMINI trials have showed that the two drugs regimen of dolutegravir+lamivudine (DTG +3TC) was noninferior to a three-drug regimen as a first line regimen for treatment-naive people living with HIV. The aim of our study was to confirm, in a real-life setting, the efficacy of this regimen. We conducted a retrospective, observational study enrolling treatment-naive patients starting a first-line regimen with lamivudine plus dolutegravir. We evaluated the virological efficacy and the immunological and metabolic profiles. Changes from baseline were evaluated through linear-mixed models for repeated measures. Linear regression analyses were performed to explore variables associated to significant changes in laboratory parameters. We analyzed a total of 20 patients: 15 (75%) were men with a median age of 34.5 years. During a cumulative time of 15.4 patients years of follow up (PYFU), we did not observe any adverse event or treatment discontinuation and all patients achieved virological suppression in the first 6 months from treatment initiation. Increase in CD4+ cells was significant at both week 24 (p = .003) and week 48 (p = .007) of follow-up. Moreover, CD4/CD8 ratio also significantly improved [median increase of +0.22 (p = .028) after 48 weeks of follow-up]. As to metabolic parameters, we observed no significant changes in total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. In a subgroup of 11 patients, we further investigate HIV-1 DNA variations. Our results are in line with the findings of the GEMINI trials, confirming the efficacy and safety of DTG +3TC in treatment-naive patients.
Comments
Be the first to comment on this protocol.